Dr. Michael Bristow

President And CEO
Medicine
ARCA Biopharma
United States of America

Biography

During 2016, we continued to make progress advancing the GENETIC-AF clinical trial evaluating Gencaro as potentially the first genetically-targeted treatment for atrial fibrillation," commented Dr. Michael Bristow, ARCA's President and Chief Executive Officer.

Research Interest

Clinical trials

Global Experts from United States of America

Global Experts in Subject

Share This Profile

Recent Expert Updates

Matthew L Stone
pediatrics
University of Virginia Health System; Charlottesville, VA
United States of America
Dr. Matthew
pediatrics
University of Virginia Health System; Charlottesville, VA
United States of America
Dr. L Stone Matthew
pediatrics
University of Virginia Health System; Charlottesville, VA
United States of America
Dr. L Stone
pediatrics
University of Virginia Health System; Charlottesville, VA
United States of America
Dr. Matthew L Stone
pediatrics
University of Virginia Health System; Charlottesville, VA
United States of America
Dr. R Sameh
pediatrics
King Abdul Aziz University
United Arab Emirates
Dr. R Ismail,
pediatrics
King Abdul Aziz University
United Arab Emirates
Sameh R Ismail,
pediatrics
King Abdul Aziz University
United Arab Emirates
Dr. Sameh R Ismail,
pediatrics
King Abdul Aziz University
United Arab Emirates
Dr. William
pediatrics
Maimonides Medical Center
United States of America